TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07732400: A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of VV-14303, an Adeno-associated Virus Vector-mediated Fibroblast Growth Factor 21 (

Sponsor: Kriya Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 56 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$987,700

Rescue Site Savings

+$649,060

Unlock Full NCT07732400 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07732400 Rescue Dossier →